Original Article

Insulin-Like Growth Factor I: a Modulator of Erythropoiesis in Uraemic Patients?

P. Ureña¹, A. Bonnardeaux¹, Kai-Uwe Eckardt², A. Kurtz² and T. B. Drücke¹
¹Département de Néphrologie and INSERM U 90, Hôpital Necker-Enfants Malades, Paris, France; ²Physiologisches Institut der Universität Zürich, Zürich, Switzerland

Abstract. Anaemia is a feature almost invariably complicating chronic renal failure. Its pathophysiology is multifactorial but the most important cause is erythropoietin (Epo) deficiency. However, either no relation or even a weakly positive relation generally exists between serum immunoreactive (i) Epo and haematocrit values in uraemic anaemia, whereas in anaemias of non-renal origin the correlation is most often strongly negative. Recent evidence indicates that growth hormone also stimulates erythropoiesis. Moreover, late erythroid progenitor cells (CFU-E) require insulin and/or insulin-like growth factor I (IGF-I) for development in vitro. IGF-I has been shown to have a synergistic action with Epo. We have measured serum iEpo and IGF-I levels in 17 haemodialysis patients with severe hyperparathyroidism (mean ± SEM serum iPTH, 988 ± 88 pg/ml). Mean age and duration of dialysis treatment were 46.1 ± 3.4 and 8.8 ± 1.0 years respectively. Mean haematocrit and haemoglobin values were 28.1 ± 1.7% and 9.39 ± 0.54 g/dl respectively. Mean serum iEpo and IGF-I levels were 20.3 ± 4.7 mU/ml and 320 ± 20 ng/ml respectively (normal values for serum iEpo and IGF-I, 17.9 ± 6 mU/ml and 91 ± 23 ng/ml respectively). We found that serum IGF-I concentrations were well correlated with haematocrit values (r = 0.68, n = 15, P<0.004) whereas serum iEpo values were not (r = 0.41, n = 12, P = 0.18). IGF-I could therefore be an important factor regulating erythropoiesis in uraemic patients, at least when associated with severe hyperparathyroidism.

Key words: Insulin-like growth factor I; IGF-I; Erythropoietin; Anaemia; Hyperparathyroidism; Uraemia; Haemodialysis

Introduction

Anaemia of moderate to severe degree is a feature which almost invariably complicates chronic renal failure (CRF). Its pathophysiology is multifactorial. Several possible mechanisms have been described and include decreased erythropoietin (Epo) production, shortened red blood cell survival, retained inhibitors or toxic substances that interfere with erythroid marrow function, iron and folate deficiency, and blood loss. However, the most important cause of end-stage renal disease anaemia clearly appears to be relative Epo deficiency [1].

Secondary hyperparathyroidism in haemodialysis patients has also been considered as a likely factor predisposing to anaemia [2,3]. However, no correlation has been found between serum intact parathyroid hormone (iPTH) [4,5] or serum immunoreactive Epo [6-8] and the severity of the anaemia in uraemic patients. Indirect evidence suggests that high serum iPTH values could be implicated in the impaired production of Epo encountered in these patients [9]. Recent findings
Serum IGF-I in Anaemia of Uraemic Patients

demonstrate that serum iEpo values increase after parathyroidectomy (PTx) in dialysis patients with secondary hyperparathyroidism [9,10]. It has also been shown that anaemia could improve after PTx in many of these patients [11-13]. In addition, hyperparathyroidism has been associated with a relative resistance to the effects of recombinant human erythropoietin (rHuEpo) treatment in dialysis patients [1].

If haematocrit does not correlate with serum Epo, other erythropoietic factors should be considered. A major candidate for this is growth hormone (GH) and its cellular mediator, insulin-like growth factor I (IGF-I). There is growing evidence indicating that GH stimulates erythropoiesis in vitro and in vivo independently from Epo [14,15]. Moreover, erythroid colony-forming units (CFU-E) require direct interaction with IGF-I and/or insulin for development [16]. It has also been suggested that insulin and IGF-II stimulate DNA synthesis and proliferation of CFU-E additively through a similar receptor or postreceptor system [17]. IGF-I has a supportive effect on the proliferation and differentiation of erythroid precursors and its action is synergistic to that of Epo [18]. Furthermore, a recent animal study has shown that during accelerated growth, IGF-I but not Epo correlates with the increase in red cell mass [19].

The purpose of the present study was to investigate whether serum IGF-I values were correlated with the degree of anaemia in dialysis patients with severe secondary hyperparathyroidism.

Methods

Patients

Seventeen consecutive patients with chronic renal failure and severe secondary hyperparathyroidism (11 men and 6 women) who were admitted to the Nephrology Department of the Necker Hospital, Paris participated in the study. Their mean (± SEM) age was 46.1 ± 3.5 years and their mean (± SEM) duration of dialysis was 8.9 ± 1.0 years. Underlying nephropathies were as follows: nephrosclerosis 2, chronic interstitial nephritis 3, polycystic kidney disease 3, chronic glomerulonephritis 3, hereditary nephropathy 2, and unknown 4. No patient was receiving rHuEpo, steroids, or androgens. None had malnutrition or hepatic dysfunction. However, the nutritional status and in particular the dietary habits of the patients have not been precisely evaluated. All patients underwent maintenance haemodialysis thrice weekly and were dialysed with their usual dialysis membranes, either of synthetic or cellulose type. Acetate or bicarbonate dialysats were used and dialysate calcium concentration was 1.75 mmol/litre.

Serum Biochemistries

Blood samples were obtained after a 12-h fast before a dialysis session. Plasma calcium was measured using atomic absorption spectrometry and plasma phosphorus using a Technicon Auto Analyzer. Plasma alkaline phosphatase activity was measured by an automated method (normal range: 30–90 IU/litre). Serum intact PTH (iPTH) was measured using a commercial radioimmunometric assay for intact human PTH (Allegro Intact PTH, Nichols Institute, San Juan Capistrano, Calif, USA). The normal range was 10–65 pg/ml. Plasma aluminium (Al) was determined using atomic absorption spectrometry with a graphite oven.

Serum insulin-like growth factor I (IGF-I) was determined after an acid–ethanol extraction as described by Daughaday et al [20], using a radioimmunoassay method (RIA) employing a rabbit antihuman IGF-I antiserum (insulin-like growth factor I/somatomedin C reagent pack for RIA, Amersham, International plc., Amersham, UK; normal range, 53–120 ng/ml; mean ± SEM, 91.9 ± 6.4 ng/ml; n = 13). Serum iEpo concentrations were determined by radioimmunoassay as described elsewhere [21]. Normal values in healthy adults with this assay are between 11 and 31 mU/ml (95% confidence interval; mean, 17.9 ± 6 mU/ml, n = 84).

Statistical Analysis

Results have been expressed as means ± SEM. The significance of the magnitude of correlation coefficients between biochemical values was assessed by linear regression analysis.

Results

Mean ± SEM concentrations of haemoglobin, haematocrit, and reticulocytes were 9.3 ± 0.5 g/dl (n = 16), 28.6 ± 1.8% (n = 15), and 52900 ± 7385 /mm³ (n = 10) respectively. Marked secondary hyperparathyroidism was present in all patients, with serum iPTH levels and plasma alkaline phosphatase activities of 988 ± 88 pg/ml (n = 17) and 461 ± 85 IU/litre (n = 17) respectively. Mean serum iEpo and IGF-I values were 20.3 ± 4.7 mU/ml (n = 13) and 320 ± 26 ng/ml (n = 17) respectively. Total plasma calcium, phosphate, and aluminium concentrations were 2.62 ± 0.06 mmol/litre (n = 17), 2.12 ± 0.13 mmol/litre (n = 17), and 1.9 ± 0.2 μmol/litre (n = 16) respectively. Serum iron and ferritin concentrations were 16.8 ± 4.0 μmol/litre (n = 15) and 274 ± 114 ng/ml (n = 15) respectively.

We found a significant linear correlation between serum IGF-I and haematocrit values as shown in Fig. 1.
By contrast, serum iEpo values were not correlated with haematocrit values (Fig. 2). No correlations were found between serum iPTH, iEpo and IGF-I or between serum iPTH and haematocrit. In addition, no correlation existed between IGF-I and the other biochemical parameters measured.

**Discussion**

In the present study we found that in an anaemic dialysis patient population with overt secondary hyperparathyroidism, not receiving rHuEpo treatment, serum IGF-I concentrations were positively correlated with haematocrit values. In contrast, no correlation was found between serum iEpo and haematocrit values.

In uraemic patients, serum iEpo values are known to be inappropriately normal or reduced in relation to the degree of anaemia and to correlate rather poorly with haematocrit [6–9]. Numerous other factors have been suggested to play a role in the anaemia of such patients including PTH excess. Several hypotheses have been proposed to explain the pathophysiology of secondary hyperparathyroidism, including a direct inhibitory effect of elevated serum iPTH on erythropoiesis and/or Epo activity [2], osteitis fibrosa with medullary fibrosis [3,11,12], hyperphosphataemia with secondary increases in red blood cell glycolytic rate, adenosine triphosphate production and 2,3-DPG formation, causing a right shift of the haemoglobin/oxygen dissociation curve and better tissue oxygenation leading to reduced Epo production [22], and finally, a possible hypercalcaemia-related decrease in Epo release [23]. However, as stated previously, no correlation could be demonstrated between serum iPTH or iEpo values [4–8] and the degree of anaemia in uraemic patients with severe hyperparathyroidism. Moreover, only the degree of marrow fibrosis appeared to predict at least partially the correction of anaemia in response to PTx [3,12]. Nevertheless, it has been suggested recently that Epo production might improve after PTx since serum iEpo may considerably increase in at least some of the patients [9,10]. This could also explain the amelioration of the anaemia after correction of the hyperparathyroid state [9].

Factors other than Epo probably play a role in regulating erythropoiesis, including insulin-like growth factors (IGFs). IGFs are known serum peptides which are structurally related to insulin, and IGF-I is secreted by the liver in response to GH secretion. They have mitogenic as well as insulin-like activities and are thought to mediate GH action in the tissue level [24,25]. IGF-I is a small molecule of 7649 Da and is bound to high-molecular-weight protein carriers of 40,000 to 15,000 Da. A certain degree of variability has been reported for serum IGF-I concentrations in uraemic patients [26–28], possibly due to methodological problems of IGF-I measurement and to the presence of plasma IGF-I binding proteins [28–30]. The results of our study, using a radioimmunoassay after acid-ethanol extraction, are in accordance with those of Andress et al [31] who found increased levels of serum IGF-I in uraemic hyperparathyroid patients.

Recently, serum IGF-I has been suggested as a marker of bone formation as well as of nutritional status in haemodialysis patients [31,32]. In addition, a slight improvement of anaemia and increased serum IGF-I concentrations were found after the administration of recombinant human GH to uraemic children on renal replacement therapy [33], and the occurrence of anaemia has been observed after the administration of a GH and IGF-I antagonist, namely somatostatin [34]. Theoretically, it is probable that IGF-I is implicated in the regulation of erythropoiesis in man. Two pieces of
evidence support this hypothesis. First, IGF-I is required for CFU-E development [14–16,35,36] and has a supportive effect on the proliferation and differentiation of erythroid precursors, in synergy with Epo [18]. Second, serum IGF-I but not serum iEpo levels, correlate with erythropoiesis during accelerated growth in rats [19].

However, to the best of our knowledge, a relationship between serum IGF-I and anaemia has not been described in uraemic patients. It has been reported that a peptide of approximately 8000 Da which was isolated from an anephric subject, was capable of regulating late erythropoiesis [37]. The N-terminal sequence of this peptide has recently been shown to be identical to that of IGF-I by Congote et al [38] who suggested that IGF-I could replace erythropoietin as a stimulator of erythropoiesis in some patients with anaemia and renal failure. Similarly, Buemi et al proposed that this peptide could be responsible for the faster and more marked response to rHuEpo observed in anephric patients [39]. It is therefore tempting to speculate that IGF-I could play an important part in the erythropoiesis of uraemic patients with anaemia.

The positive correlation between IGF-I and haematocrit values had a coefficient of only 0.68. This could be partly due to the action of other erythroid colony-stimulating hormones such as Epo but also to a decreased IGF-I activity in uraemic serum secondary to the accumulation of a low-molecular-weight inhibitor normally cleared by the kidney [29,31]. The latter could lead to a decreased tissue sensitivity to IGF-I. A similar mechanism of end-organ resistance to GH has been proposed to explain growth retardation in uraemia despite elevated serum GH levels [40].

In summary, we have found that immunoreactive serum IGF-I but not iEpo values directly correlated with haematocrit in haemodialysis patients with severe secondary hyperparathyroidism. IGF-I could be an important factor regulating erythropoiesis in uraemic patients. Further studies are needed to characterise this correlation and possible interactions with the nutritional status and other variables in order to define the precise role of IGF-I in the anaemia of uraemic patients with and without secondary hyperparathyroidism.

References


*Received for publication 2.1.91*  
*Accepted in revised form 18.6.91*